DUBLIN–(BUSINESS WIRE)–Feb 9, 2021– The "Histamine H4 Receptor – Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com’s offering. According to this report Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 6 molecules. Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function. The report ‘Histamine H4 Receptor – Pipeline Review, H2 2020’ outlays comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities. It also reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 1 and 4 respectively. Report covers products from therapy areas Dermatology, Ear Nose Throat Disorders, Immunology, Ophthalmology and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Sensorineural Hearing Loss, Age Related Macular Degeneration, Allergic Conjunctivitis, Allergies, Cystic Fibrosis, Hearing Disorders and Idiopathic Pulmonary Fibrosis. Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Topics Covered: 1. Introduction
- Report Coverage
2. Overview 3. Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
4. Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
5. Companies Involved in Therapeutics Development
- Bioprojet SCR
- Chrysalis Pharma SAS
- JW Pharmaceutical Corp
- Sensorion SA
- Sosei Heptares
6. Drug Profiles 7. Dormant Products 8. Discontinued Products 9. Product Development Milestones
- Featured News & Press Releases
- Jul 16, 2020: Sensorion hosting key opinion leader call with Dr. Michael Hoffer on sudden sensorineural hearing loss and SENS-401 as a Potential Treatment Option on July 23, 2020
- Mar 16, 2020: Covid-19: Sensorion delays Phase ll trial due to slow recruitment rate
- Feb 18, 2020: Sensorion gets approval to add new sites to Phase II trial of SENS-401
- Feb 03, 2020: Sensorion to attend and present at LSX World Congress 2020
- Jan 30, 2020: Sensorion presents new SENS-401 preclinical data at ARO Midwinter Meeting 2020
- Jan 10, 2020: Sensorion announces its presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference
- Dec 23, 2019: Sensorion announces positive data safety monitoring board review of Phase 2 trial for SENS-401 in Sudden Sensorineural Hearing Loss
- Dec 23, 2019: Sensorion announces ?5.6m non-dilutive funding to support SENS-401 Phase 2 study in Sudden Sensorineural Hearing Loss French ministry of armed forces to participate in the study
- Nov 20, 2019: Drug tested for sudden hearing loss
- Nov 07, 2019: Sensorion announces an oral presentation of new SENS-401 preclinical data at ISIET 2019 in Hannover
- Oct 23, 2019: Sensorion announce collaboration announces a poster presentation of new SENS-401 preclinical data at SFN 2019 in Chicago
- Sep 11, 2019: Sensorion announces three presentations at IEB 2019 in Padua
- Aug 27, 2019: LEO Pharma files IND application to FDA for a clinical study of JW1601/LP0190 in the US
- Jul 11, 2019: Sensorion receives FDA IND Approval for Arazasetron (SENS-401)
- Jun 28, 2019: Sensorion’s PIP is EMA-approved for two indications
10. Appendix For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dydonb View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005876/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/09/2021 10:40 AM/DISC: 02/09/2021 10:40 AM http://www.businesswire.com/news/home/20210209005876/en
